Prot #NUDB 12I03: Evaluation of Octreotide LAR Dose Optimization and Clinical Outcomes in Patients with Neuroendocrine Tumors: a Neuroendocrine Database Analysis

Project: Research project

Project Details

StatusFinished
Effective start/end date12/3/12 → 11/30/18

Funding

  • Novartis Pharmaceuticals Corporation (Prot #NUDB 12I03)